Xcorporeal (Xcorporeal) Change In Receivables : $-0.01 Mil (TTM As of Sep. 2009)

View and export this data going back to . Start your Free Trial

What is Xcorporeal Change In Receivables?

Xcorporeal's change in receivables for the quarter that ended in Sep. 2009 was $-0.01 Mil. It means Xcorporeal's Accounts Receivable increased by $0.01 Mil from Jun. 2009 to Sep. 2009 .

Xcorporeal's change in receivables for the fiscal year that ended in Dec. 2008 was $-0.09 Mil. It means Xcorporeal's Accounts Receivable increased by $0.09 Mil from Dec. 2007 to Dec. 2008 .

Xcorporeal's Accounts Receivable for the quarter that ended in Sep. 2009 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Xcorporeal's liquidation value for the three months ended in Sep. 2009 was $-3.80 Mil.

Xcorporeal Change In Receivables Historical Data

The historical data trend for Xcorporeal's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal Change In Receivables Chart

Xcorporeal Annual Data

Trend

Feb99

Feb00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Change In Receivables

Get a 7-Day Free Trial

-0.09

Xcorporeal Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-0.01

Xcorporeal Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Xcorporeal (GREY:XCRP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Xcorporeal's Days Sales Outstanding for the quarter that ended in Sep. 2009 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Xcorporeal's accounts receivable are only considered to be worth 75% of book value:

Xcorporeal's liquidation value for the quarter that ended in Sep. 2009 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.324	-	4.127	+	0.75 * 0	+	0.5 * 0
=	-3.80

Xcorporeal Change In Receivables Related Terms

Thank you for viewing the detailed overview of Xcorporeal's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Xcorporeal (Xcorporeal) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Empire Drive, Lake Forest, CA, USA, 92630

Website

Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.

Executives

Kelly J. Mccrann	director, officer: Chairman and CEO	11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger	officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins	director	C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc	10 percent owner	135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer	director, 10 percent owner, officer: Executive Chairman	11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf	director	981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen	director	22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte	10 percent owner	C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122